| Literature DB >> 31530345 |
Marion Hutinel1,2, Patricia Maria Catharina Huijbers1,2, Jerker Fick3, Christina Åhrén1,2,4, Dan Göran Joakim Larsson1,2, Carl-Fredrik Flach1,2.
Abstract
IntroductionThe occurrence of antibiotic resistance in faecal bacteria in sewage is likely to reflect the current local clinical resistance situation.AimThis observational study investigated the relationship between Escherichia coli resistance rates in sewage and clinical samples representing the same human populations.MethodsE. coli were isolated from eight hospital (n = 721 isolates) and six municipal (n = 531 isolates) sewage samples, over 1 year in Gothenburg, Sweden. An inexpensive broth screening method was validated against disk diffusion and applied to determine resistance against 11 antibiotics in sewage isolates. Resistance data on E. coli isolated from clinical samples from corresponding local hospital and primary care patients were collected during the same year and compared with those of the sewage isolates by linear regression.ResultsE. coli resistance rates derived from hospital sewage and hospital patients strongly correlated (r2 = 0.95 for urine and 0.89 for blood samples), as did resistance rates in E. coli from municipal sewage and primary care urine samples (r2 = 0.82). Resistance rates in hospital sewage isolates were close to those in hospital clinical isolates while resistance rates in municipal sewage isolates were about half of those measured in primary care isolates. Resistance rates in municipal sewage isolates were more stable between sampling occasions than those from hospital sewage.ConclusionOur findings provide support for development of a low-cost, sewage-based surveillance system for antibiotic resistance in E. coli, which could complement current monitoring systems and provide clinically relevant antibiotic resistance data for countries and regions where surveillance is lacking.Entities:
Keywords: Escherichia coli; antibiotic resistance; antimicrobial resistance; sewage; surveillance; wastewater
Mesh:
Substances:
Year: 2019 PMID: 31530345 PMCID: PMC6749774 DOI: 10.2807/1560-7917.ES.2019.24.37.1800497
Source DB: PubMed Journal: Euro Surveill ISSN: 1025-496X
Annual means of the resistance rates in Escherichia coli isolated from hospital and municipal sewage, Gothenburg, Sweden, 2016 (n = 1,252)
| Resistance phenotype | Mean resistance ratesa, % | p valueb | |
|---|---|---|---|
| Hospital sewage | Municipal sewage | ||
| Amoxicillin-clavulanic acid | 19.4 | 9.7 | < 0.001 |
| Cefadroxil | 8.8 | 5.7 | 0.046 |
| Cefotaxime | 5.5 | 2.0 | 0.002 |
| Ceftazidime | 5.2 | 1.4 | < 0.001 |
| Ciprofloxacin | 11.6 | 4.7 | < 0.001 |
| Mecillinam | 2.0 | 4.2 | 0.030 |
| Nitrofurantoin | 0.9 | 0.0 | 0.046 |
| Piperacillin-tazobactam | 0.9 | 0.3 | 0.316 |
| Tobramycin | 5.1 | 0.4 | < 0.001 |
| Trimethoprim | 21.7 | 11.7 | < 0.001 |
| Trimethoprim-sulfamethoxazole | 19.6 | 10.8 | < 0.001 |
| ESBLs | 5.5 | 1.8 | < 0.001 |
ESBLs: extended spectrum beta-lactamase-producing E. coli.
a Mean of the resistance rates measured for the different sampling occasions in 2016. The rates at each sampling occasion are detailed in Tables 2 and 3 for hospital and municipal sewage, respectively.
b p value of Fisher’s exact test comparing overall resistance rates (cumulative data for all sampling occasions) from hospital and municipal sewage.
Resistance rates in Escherichia coli isolated from hospital sewage, Gothenburg, Sweden, 2016 (n = 721)
| Resistance phenotype | Sampling occasion | p valueb | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21 Jan | 22 Mar | 30 Mar | 3 May | 22 Jun | 28 Sep | 15 Nov | 20 Dec | ||||||||||
| na | % | na | % | na | % | na | % | na | % | na | % | na | % | na | % | ||
| Amoxicillin-clavulanic acid | 23 | 24.0 | 6 | 7.1 | 18 | 18.8 | 13 | 21.0 | 22 | 22.9 | 29 | 30.2 | 11 | 11.6 | 19 | 19.8 | 0.001 |
| Cefadroxil | 4 | 4.2 | 2 | 2.4 | 8 | 8.3 | 11 | 17.7 | 14 | 14.6 | 4 | 4.2 | 5 | 5.3 | 13 | 13.5 | < 0.001 |
| Cefotaxime | 1 | 1.0 | 1 | 1.2 | 4 | 4.2 | 7 | 11.3 | 11 | 11.5 | 2 | 2.1 | 3 | 3.2 | 9 | 9.4 | < 0.001 |
| Ceftazidime | 3 | 3.1 | 0 | 0.0 | 3 | 3.1 | 5 | 8.1 | 11 | 11.5 | 2 | 2.1 | 3 | 3.2 | 10 | 10.4 | 0.002 |
| Ciprofloxacin | 4 | 4.2 | 2 | 2.4 | 1 | 1.0 | 3 | 4.8 | 51 | 53.1 | 5 | 5.2 | 6 | 6.3 | 15 | 15.6 | < 0.001 |
| Mecillinam | 3 | 3.1 | 0 | 0.0 | 3 | 3.1 | 0 | 0.0 | 3 | 3.1 | 4 | 4.2 | 1 | 1.1 | 1 | 1.0 | 0.368 |
| Nitrofurantoin | 0 | 0.0 | 0 | 0.0 | 1 | 1.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | 2.1 | 4 | 4.2 | 0.029 |
| Piperacillin-tazobactam | 1 | 1.0 | 0 | 0.0 | 2 | 2.1 | 0 | 0.0 | 1 | 1.0 | 0 | 0.0 | 1 | 1.1 | 2 | 2.1 | 0.797 |
| Tobramycin | 3 | 3.1 | 0 | 0.0 | 1 | 1.0 | 5 | 8.1 | 10 | 10.4 | 3 | 3.1 | 4 | 4.2 | 10 | 10.4 | < 0.001 |
| Trimethoprim | 29 | 30.2 | 10 | 11.9 | 27 | 28.1 | 11 | 17.7 | 19 | 19.8 | 32 | 33.3 | 6 | 6.3 | 25 | 26.0 | < 0.001 |
| Trimethoprim-sulfamethoxazole | 23 | 24.0 | 9 | 10.7 | 26 | 27.1 | 7 | 11.3 | 18 | 18.8 | 32 | 33.3 | 6 | 6.3 | 24 | 25.0 | < 0.001 |
| ESBLs | 2 | 2.1 | 1 | 1.2 | 4 | 4.2 | 6 | 9.7 | 11 | 11.5 | 2 | 2.1 | 3 | 3.2 | 10 | 10.4 | 0.003 |
ESBLs: extended spectrum beta-lactamase-producing E. coli.
a As some isolates could be resistant to more than one antibiotic, the sum of values presented in the subcolumn can exceed the total number of isolates analysed on the sampling occasion, which is presented in the main column header in parentheses.
b p value of Fisher’s exact test comparing the different sampling occasions.
Resistance rates in Escherichia coli isolated from municipal sewage, Gothenburg, Sweden, 2016 (n = 531)
| Resistance phenotype | Sampling occasion | p valueb | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21 Jan | 30 Mar | 3 May | 14 Jun | 23 Aug | 29 Nov | ||||||||
| na | % | na | % | na | % | na | % | na | % | na | % | ||
| Amoxicillin-clavulanic acid | 12 | 12.6 | 8 | 7.0 | 8 | 8.4 | 4 | 9.5 | 10 | 9.6 | 9 | 11.3 | 0.790 |
| Cefadroxil | 6 | 6.3 | 4 | 3.5 | 3 | 3.2 | 3 | 7.1 | 8 | 7.7 | 5 | 6.3 | 0.609 |
| Cefotaxime | 3 | 3.2 | 2 | 1.7 | 0 | 0.0 | 1 | 2.4 | 2 | 1.9 | 2 | 2.5 | 0.603 |
| Ceftazidime | 3 | 3.2 | 1 | 0.9 | 0 | 0.0 | 0 | 0.0 | 2 | 1.9 | 2 | 2.5 | 0.467 |
| Ciprofloxacin | 4 | 4.2 | 4 | 3.5 | 3 | 3.2 | 3 | 7.1 | 4 | 3.8 | 5 | 6.3 | 0.814 |
| Mecillinam | 6 | 6.3 | 4 | 3.5 | 2 | 2.1 | 1 | 2.4 | 6 | 5.8 | 4 | 5.0 | 0.690 |
| Nitrofurantoin | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | NA |
| Piperacillin-tazobactam | 0 | 0.0 | 0 | 0.0 | 1 | 1.1 | 0 | 0.0 | 1 | 1.0 | 0 | 0.0 | 0.760 |
| Tobramycin | 1 | 1.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 1.3 | 0.431 |
| Trimethoprim | 11 | 11.6 | 8 | 7.0 | 13 | 13.7 | 7 | 16.7 | 9 | 8.7 | 10 | 12.5 | 0.401 |
| Trimethoprim-sulfamethoxazole | 10 | 10.5 | 8 | 7.0 | 11 | 11.6 | 6 | 14.3 | 9 | 8.7 | 10 | 12.5 | 0.650 |
| ESBLs | 3 | 3.2 | 1 | 0.9 | 0 | 0.0 | 1 | 2.4 | 2 | 1.9 | 2 | 2.5 | 0.474 |
ESBLs: extended spectrum beta-lactamase-producing E. coli.
a As some isolates could be resistant to more than one antibiotic, the sum of values presented in the subcolumn can exceed the total number of isolates analysed on the sampling occasion, which is presented in the main column header in parentheses.
b p value of Fisher’s exact test comparing the different sampling occasions.
Resistance rates in Escherichia coli isolated from clinical samples, Gothenburg, Sweden, 2016 (n = 6,270)
| Resistance phenotype | Type of clinical sample | p value | p value | |||||
|---|---|---|---|---|---|---|---|---|
| Hospital blood | Hospital urine | Primary care urine | ||||||
| n | % | n | % | n | % | |||
| Amoxicillin-clavulanic acid | NA | 245 | 24.4a | 1,141 | 23.4b | NA | 0.487 | |
| Cefadroxil | NA | 99 | 9.0a | 232 | 4.7 | NA | < 0.001 | |
| Cefotaxime | 11 | 5.8 | 82 | 7.5a | 194 | 3.9 | 0.542 | < 0.001 |
| Ceftazidime | 9 | 4.8 | 69 | 6.3a | 152 | 3.0 | 0.510 | < 0.001 |
| Ciprofloxacin | 28 | 14.8 | 143 | 13.0 | 379 | 7.6 | 0.488 | < 0.001 |
| Mecillinam | NA | 62 | 5.7 | 232 | 4.7 | NA | 0.162 | |
| Nitrofurantoin | NA | 16 | 1.5 | 47 | 0.9 | NA | 0.137 | |
| Piperacillin-tazobactam | 5 | 2.6 | NA | NA | NA | NA | ||
| Tobramycin | 6 | 3.2 | NA | NA | NA | NA | ||
| Trimethoprim | NA | 249 | 22.7 | 1,036 | 20.8 | NA | 0.164 | |
| Trimethoprim-sulfamethoxazole | 44 | 23.3 | NA | NA | NA | NA | ||
| ESBLs | 12 | 6.3 | 81 | 7.4a | 177 | 3.6b | 0.761 | < 0.001 |
ESBLs: extended spectrum beta-lactamase-producing E. coli; NA: not applicable.
a Resistance rates were generally calculated for 1,097 isolates from hospital patients’ urine with the exception of amoxicillin-clavulanic acid, cefadroxil, cefotaxime, ceftazidime and ESBLs for which 1,003; 1,096; 1,096; 1,096 and 1,088 isolates, respectively, were tested.
b Resistance rates were generally calculated for 4,984 isolates from primary care patients’ urine with the exception of amoxicillin-clavulanic acid and ESBLs for which 4,880 and 4,967 isolates, respectively, were tested.
c p value of Fisher’s exact tests comparing blood and urine samples from the hospital.
d p value of Fisher’s exact tests comparing urine samples from hospital and primary care.
Figure 1Mean resistance rates in Escherichia coli isolated from hospital sewage samples compared with those isolated from (A) urine and (B) blood samples from the same hospital, Gothenburg, Sweden, 2016 (n = 2,007)
Figure 2Mean resistance rates in Escherichia coli isolated from influent samples collected at the municipal WWTP compared with those isolated from urine from primary care patients in the region served by the WWTP, Gothenburg, Sweden, 2016 (n = 5,515)